25 MILYONG SINOPHARM VACCINE, HANDANG IPADALA SA BANSA SA PANAHONG MAAPRUBAHAN ANG EUA NITO

Ni Monica N. Ladisla
Source: PNA
Share on facebook
Facebook
Share on twitter
Twitter
Share on email
Email

Handa umanong magbigay ng 25 milyong doses ng Sinopharm ang China Biotechnology Co. Ltd. sa panahong maaprubahan ng Food and Drug Administration ang kanilang emergency use authorization.

Ayon kay Atty. Mark Kristopher Tolentino, President at CEO ng MKG Universal Drugs Trading Corp. na siyang itinalaga bilang eksklusibong distributor ng Sinopharm vaccine sa bansa, may kakayanan umano ang China Biotech na magpadala ng 25 milyong doses ng bakuna sa Pilipinas.

“Once we get FDA approval, we can have the Sinopharm vaccine here in just one week, to be delivered by plane,” ani Tolentino.

Sa kasalukuyan umano, hinihintay na lamang nila na maaprubahan ng FDA ang emergency use authorization na isinumite nila noong Enero.

Aniya, sa panahong makuha ang EUA, may kapasidad umano ang Sinopharm na mabakunahan ang buong populasyon ng bansa sa lalong madaling panahon.

“Sinopharm is China’s best vaccine, and is strongly recommended for both the young (three years old) and the old (up to 100 years old), as well as for those with underlying diseases and comorbidities. It is also suitable for Asians,” paliwanag ni Tolentino.

Sa datos na lumabas mula sa clinical trials na isinagawa noong Hunyo 2020 sa United Arab Emirates, 1,500 umano sa mga lumahok ay mga Pilipino at walang naitalang adverse effects matapos mabakunahan ang mga ito.

CONTACT US

Anchored on its mantra, “Sentro ng Katotohanan, Tapat sa Mamamayan”, Balita Central Digital complements and supports the Balita Central newspaper published bi-monthly to combat fake news and to provide the public with easy-to-digest news bits that are sourced solely from the Presidency and government agencies. 

Balita Central is under the supervision of the Bureau of Communications Services (BCS), one of the attached agencies of the Presidential Communications Operations Office (PCOO).

Launched on February 28, 2019 at the Manila Light Rail Transit System Line 2 (LRT-2) Cubao Station, Quezon City, it also aims to raise awareness among local communities about the policies, programs, and accomplishments of the Presidency. 

Through this platform, Balita Central Digital aims to reach further the online community to deliver more accurate information and communication services in order to educate the citizenry regarding national issues which would enlighten them to be engaged and be empowered in contributing to building a better nation.

Balita Central is situated at the BCS Headquarters located beside the Philippine Cancer Society along San Rafael, San Miguel, Malacañang Complex, Manila City. Its official website address is balitacentral.ph.

For inquiries and feedback, Balita Central may be contacted at editorialdesk.bcs@gmail.com.